PTO/SB/96 (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Pfizer Inc.	
Application No./Patent No.: 10/598,810	Filed/Issue Date: September 12, 2006
Titled: Pharmaceutical Formulations	
Pfizer Inc.	a corporation
(Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
states that it is:	
1. X the assignee of the entire right, title, and inte	rest in;
an assignee of less than the entire right, title (The extent (by percentage) of its ownership	, and interest in interest is %); or
3. the assignee of an undivided interest in the	entirety of (a complete assignment from one of the joint inventors was made)
the patent application/patent identified above, by virtue o	
the United States Patent and Trademark Off copy therefore is attached.	tent application/patent identified above. The assignment was recorded in ce at Reel, Frame, or for which a
OR  B. X A chain of title from the inventor(s), of the pa	tent application/patent identified above, to the current assignee as follows:
1. From: Stephen McAllister, Ronald F	
	United States Patent and Trademark Office at
	rame 0199 or for which a copy thereof is attached.
2. From: SmithKline Beecham p.l.c.	To: SmithKline Beecham Limited
00.00	United States Patent and Trademark Office at
h-baseabaseau, appropriate the second	rame 0679 or for which a copy thereof is attached.
3 From: SmithKline Beecham Limited	To: Pfizer Inc.
The document was recorded in the	United States Patent and Trademark Office at
Reel <u>025833</u> , F	rame 0373 or for which a copy thereof is attached.
Additional documents in the chain of title are	listed on a supplemental sheet(s).
As required by 37 CFR 3.73(b)(1)(i), the docume or concurrently is being, submitted for recordation	ntary evidence of the chain of title from the original owner to the assignee was, pursuant to 37 CFR 3.11.
[NOTE: A separate copy (i.e., a true copy of the accordance with 37 CFR Part 3, to record the ass	original assignment document(s)) must be submitted to Assignment Division in ignment in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is author	ized to act on behalf of the assignee.
Vy Dr	2-None 2011
// Signature	Date
G/egg/C Benson	VP & Asst. General Counsel
∖ Frinted or Typed Name	Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Chain of Title Supplemental Sheet page 2 of 2

Application No./Patent No.: 10/598,810 Filed/Issue Date: September 12, 2006

Entitled: "Pharmaceutical Formulations"

A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Adrian Brown, Daniel Margetson, Wayne M. Matthews To: SmithKline Beecham p.l.c.

The document was recorded in the United States Patent and Trademark Office at Reel  $\underline{019300}$  Frame  $\underline{0199}$ , or for which a copy thereof is attached.